28.12
-0.935(-3.22%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
1800
First IPO Date
July 16, 1991
| Name | Title | Pay | Year Born |
| Mr. Richard F. Pops | Chairman & Chief Executive Officer | 2.45M | 1962 |
| Mr. C. Todd Nichols | Senior Vice President & Chief Commercial Officer | 912,690 | 1970 |
| Mr. David Joseph Gaffin J.D. | Executive Vice President, Chief Legal Officer, Chief Compliance Officer & Secretary | 1.08M | 1972 |
| Mr. Blair C. Jackson | Interim Principal Financial Officer, Executive Vice President, Chief Risk Officer & Chief Operating Officer | 1.2M | 1973 |
| Dr. Craig C. Hopkinson M.D. | Executive Vice President of Research & Development and Chief Medical Officer | 1.25M | 1969 |
| Mr. Thomas Harvey | Chief Information Officer & Senior Vice President of IT | 0 | N/A |
| Mr. Stephen Schiavo | Senior Vice President & Chief Human Resources Officer | 0 | N/A |
| Mr. Samuel J. Parisi | Interim Principal Accounting Officer & Vice President of Finance | 0 | 1975 |
| Mr. Peter Norman | Senior Vice President of Policy & Government Relations | 0 | N/A |
| Ms. Sandra Coombs | Senior Vice President of Corporate Affairs & Investor Relations | 0 | N/A |
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.